Anemia of inflammation (AI), the second prevalent anemia, is associated with worse prognosis and increased mortality in numerous chronic diseases. We recently reported that the gasotransmitter hydrogen sulfide (H2S) suppressed the inflammatory activation of signal transducer and activator of transcription 3 (STAT3) and hepcidin, the critical mediators of AI. Adenosine 5′-monophosphate-activated protein kinase (AMPK) is a novel inflammatory regulator and might be activated by H2S. In this study, we determined whether AMPK played a role in H2S-mediated anti-inflammatory response in AI and evaluated the therapeutic potential of AMPK against AI by pharmacological and clinical approaches.
Results:
We showed that AMPK mediated the inhibition of STAT3, hepcidin, and AI by H2S during inflammation. Moreover, pharmacological and genetic activation of AMPK ameliorated hepcidin production, corrected iron dysregulation, and relieved hypoferremia and anemia in both acute and chronic inflammation models in mice. Mechanistic studies indicated that AMPK suppressed STAT3/hepcidin activation by promoting proteasome-mediated Janus kinase 2 (JAK2) degradation, which was dependent on the intact function of suppressor of cytokine signaling 1 (SOCS1) and increased interactions between SOCS1 and JAK2. Most importantly, the AMPK activator metformin was associated with decreased serum hepcidin content and anemia morbidity in Chinese type 2 diabetes mellitus patients.
Innovation:
This is the first study to demonstrate the inhibition of inflammatory hepcidin and AI by AMPK-induced JAK2 degradation. Our work uncovered AMPK as a novel therapeutic target, and metformin as a potential therapy against AI.
Conclusion:
The present work demonstrated that AMPK mediated the therapeutic effects of H2S and relieved AI by promoting SOCS1-mediated JAK2 degradation. Antioxid. Redox Signal. 27, 251–268.
Get full access to this article
View all access options for this article.
References
1.
AndrewsM, SotoN, and Arredondo-OlguínM. Association between ferritin and hepcidin levels and inflammatory status in patients with type 2 diabetes mellitus and obesity. Nutrition, 31: 51–57, 2015.
2.
ArodaVR, EdelsteinSL, GoldbergRB, KnowlerWC, MarcovinaSM, OrchardTJ, BrayGA, SchadeDS, TemprosaMG, and WhiteNH. Long-term metformin use and vitamin B12 deficiency in the Diabetes Prevention Program Outcomes Study. J Clin Endocrinol Metab, 101: 1754–1761, 2016.
3.
BohliusJ, SchmidlinK, BrillantC, SchwarzerG, TrelleS, SeidenfeldJ, ZwahlenM, ClarkeM, WeingartO, and KlugeS. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet, 373: 1532–1542, 2009.
4.
CabreiroF, AuC, LeungK-Y, Vergara-IrigarayN, CocheméHM, NooriT, WeinkoveD, SchusterE, GreeneND, and GemsD. Metformin retards aging in C. elegans by altering microbial folate and methionine metabolism. Cell, 153: 228–239, 2013.
5.
CalabreseV, MalletteFA, Deschênes-SimardX, RamanathanS, GagnonJ, MooresA, IlangumaranS, and FerbeyreG. SOCS1 links cytokine signaling to p53 and senescence. Mol Cell, 36: 754–767, 2009.
6.
CantóC, Gerhart-HinesZ, FeigeJN, LagougeM, NoriegaL, MilneJC, ElliottPJ, PuigserverP, and AuwerxJ. AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature, 458: 1056–1060, 2009.
7.
CaoY, LiH, LiuH, ZhengC, JiH, and LiuX. The serine/threonine kinase LKB1 controls thymocyte survival through regulation of AMPK activation and Bcl-XL expression. Cell Res, 20: 99–108, 2010.
8.
CaroJJ, SalasM, WardA, and GossG. Anemia as an independent prognostic factor for survival in patients with cancer. Cancer, 91: 2214–2221, 2001.
9.
CraigKJ, WilliamsJD, RileySG, SmithH, OwensDR, WorthingD, CavillI, and PhillipsAO. Anemia and diabetes in the absence of nephropathy. Diabetes Care, 28: 1118–1123, 2005.
10.
DaySM, DuquaineD, MundadaLV, MenonRG, KhanBV, RajagopalanS, and FayWP. Chronic iron administration increases vascular oxidative stress and accelerates arterial thrombosis. Circulation, 107: 2601–2606, 2003.
11.
de JongeWJ, van der ZandenEP, TheFO, BijlsmaMF, van WesterlooDJ, BenninkRJ, BerthoudH-R, UematsuS, AkiraS, and van den WijngaardRM. Stimulation of the vagus nerve attenuates macrophage activation by activating the Jak2-STAT3 signaling pathway. Nat Immunol, 6: 844–851, 2005.
12.
DikowR, SchwengerV, SchömigM, and RitzE. How should we manage anaemia in patients with diabetes?. Nephrol Dial Transplant, 17: 67–72, 2002.
13.
DowlingRJ, ZakikhaniM, FantusIG, PollakM, and SonenbergN. Metformin inhibits mammalian target of rapamycin–dependent translation initiation in breast cancer cells. Cancer Res, 67: 10804–10812, 2007.
14.
El-AchkarTM, OhmitSE, Mccullough PAD C, ROOKE, BrownWW, GrimmR, BakrisGL, KeaneWF, and FlackJM. Higher prevalence of anemia with diabetes mellitus in moderate kidney insufficiency: the Kidney Early Evaluation Program. Kidney Int, 67: 1483–1488, 2005.
15.
FaubertB, BoilyG, IzreigS, GrissT, SamborskaB, DongZ, DupuyF, ChambersC, FuerthBJ, and ViolletB. AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo. Cell Metab, 17: 113–124, 2013.
16.
FoleyRN, ParfreyPS, HarnettJD, KentGM, MurrayDC, and BarrePE. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis, 28: 53–61, 1996.
17.
GanzT. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood, 102: 783–788, 2003.
18.
GanzT and NemethE. Iron sequestration and anemia of inflammation. Semin Hematol, 46: 387–393, 2009.
19.
GrossmanC, DovrishZ, Koren-MoragN, BornsteinG, and LeibowitzA. Diabetes mellitus with normal renal function is associated with anaemia. Diabetes Metab Res Rev, 30: 291–296, 2014.
20.
GroupDPPR. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med, 346: 393, 2002.
21.
HorwichTB, FonarowGC, HamiltonMA, MacLellanWR, and BorensteinJ. Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol, 39: 1780–1786, 2002.
22.
IkedaT, IwataK, and MurakamiH. Inhibitory effect of metformin on intestinal glucose absorption in the perfused rat intestine. Biochem Pharmacol, 59: 887–890, 2000.
23.
IshimuraE, NishizawaY, OkunoS, MatsumotoN, EmotoM, InabaM, KawagishiT, KimC-W, and MoriiH. Diabetes mellitus increases the severity of anemia in non-dialyzed patients with renal failure. J Nephrol, 11: 83–86, 1997.
24.
JiangF, SunZ-Z, TangY-T, XuC, and JiaoX-Y. Hepcidin expression and iron parameters change in Type 2 diabetic patients. Diabetes Res Clin Pract, 93: 43–48, 2011.
25.
JiangR, MansonJE, MeigsJB, MaJ, RifaiN, and HuFB. Body iron stores in relation to risk of type 2 diabetes in apparently healthy women. JAMA, 291: 711–717, 2004.
26.
JiangW, WangS, XiaoM, LinY, ZhouL, LeiQ, XiongY, GuanK-L, and ZhaoS. Acetylation regulates gluconeogenesis by promoting PEPCK1 degradation via recruiting the UBR5 ubiquitin ligase. Mol Cell, 43: 33–44, 2011.
27.
KahnBB, AlquierT, CarlingD, and HardieDG. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab, 1: 15–25, 2005.
28.
KellyM, KellerC, AviluceaPR, KellerP, LuoZ, XiangX, GiraltM, HidalgoJ, SahaAK, and PedersenBK. AMPK activity is diminished in tissues of IL-6 knockout mice: the effect of exercise. Biochem Biophys Res Commun, 320: 449–454, 2004.
29.
KemnaE, PickkersP, NemethE, van der HoevenH, and SwinkelsD. Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS. Blood, 106: 1864–1866, 2005.
30.
KileBT, SchulmanBA, AlexanderWS, NicolaNA, MartinHM, and HiltonDJ. The SOCS box: a tale of destruction and degradation. Trends Biochem Sci, 27: 235–241, 2002.
31.
KimJ, KunduM, ViolletB, and GuanK-L. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol, 13: 132–141, 2011.
32.
KimuraY, DarguschR, SchubertD, and KimuraH. Hydrogen sulfide protects HT22 neuronal cells from oxidative stress. Antioxid Redox Signal, 8: 661–670, 2006.
33.
KimuraY, GotoY-I, and KimuraH. Hydrogen sulfide increases glutathione production and suppresses oxidative stress in mitochondria. Antioxid Redox Signal, 12: 1–13, 2010.
34.
LangdonJM, YatesSC, FemnouLK, McCranorBJ, CheadleC, XueQL, VaulontS, CivinCI, WalstonJD, and RoyCN. Hepcidin-dependent and hepcidin-independent regulation of erythropoiesis in a mouse model of anemia of chronic inflammation. Am J Hematol, 89: 470–479, 2014.
35.
LeeP, PengH, GelbartT, and BeutlerE. The IL-6-and lipopolysaccharide-induced transcription of hepcidin in HFE-, transferrin receptor 2-, and β2-microglobulin-deficient hepatocytes. Proc Natl Acad Sci U S A, 101: 9263–9265, 2004.
36.
LeonardWJ and O'SheaJJ. Jaks and STATs: biological implications. Annu Rev Immunol, 16: 293–322, 1998.
37.
LiL, BhatiaM, and MoorePK. Hydrogen sulphide—a novel mediator of inflammation?. Curr Opin Pharmacol, 6: 125–129, 2006.
38.
LiL, RoseP, and MoorePK. Hydrogen sulfide and cell signaling. Annu Rev Pharmacol Toxicol, 51: 169–187, 2011.
39.
LiX, WangL, ZhouXE, KeJ, de WaalPW, GuX, TanME, WangD, WuD, and XuHE. Structural basis of AMPK regulation by adenine nucleotides and glycogen. Cell Res, 25: 50–66, 2015.
40.
LibbyG, DonnellyLA, DonnanPT, AlessiDR, MorrisAD, and EvansJM. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care, 32: 1620–1625, 2009.
41.
LinR, TaoR, GaoX, LiT, ZhouX, GuanK-L, XiongY, and LeiQ-Y. Acetylation stabilizes ATP-citrate lyase to promote lipid biosynthesis and tumor growth. Mol Cell, 51: 506–518, 2013.
42.
LuJ, QianY, AltieriM, DongH, WangJ, RainaK, HinesJ, WinklerJD, CrewAP, and ColemanK. Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4. Chem Biol, 22: 755–763, 2015.
43.
Martin-MontalvoA, MerckenEM, MitchellSJ, PalaciosHH, MotePL, Scheibye-KnudsenM, GomesAP, WardTM, MinorRK, and BlouinM-J. Metformin improves healthspan and lifespan in mice. Nat Commun, 4: 2192, 2013.
44.
MihaylovaMM and ShawRJ. The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat Cell Biol, 13: 1016–1023, 2011.
45.
MinamishimaS, BougakiM, SipsPY, De YuJ, MinamishimaYA, ElrodJW, LeferDJ, BlochKD, and IchinoseF. Hydrogen sulfide improves survival after cardiac arrest and cardiopulmonary resuscitation via a nitric oxide synthase 3–dependent mechanism in mice. Circulation, 120: 888–896, 2009.
46.
MurrayPJ. The JAK-STAT signaling pathway: input and output integration. J Immunol, 178: 2623–2629, 2007.
47.
NemethE and GanzT. Anemia of inflammation. Hematol Oncol Clin North Am, 28: 671–681, 2014.
48.
NemethE, RiveraS, GabayanV, KellerC, TaudorfS, PedersenBK, and GanzT. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest, 113: 1271–1276, 2004.
49.
NemethE, ValoreEV, TerritoM, SchillerG, LichtensteinA, and GanzT. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood, 101: 2461–2463, 2003.
50.
NicolasG, ChauvetC, ViatteL, DananJL, BigardX, DevauxI, BeaumontC, KahnA, and VaulontS. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest, 110: 1037–1044, 2002.
51.
O'MearaE, ClaytonT, McEntegartMB, McMurrayJJ, LangCC, RogerSD, YoungJB, SolomonSD, GrangerCB, and ÖstergrenJ. Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Circulation, 113: 986–994, 2006.
52.
O'NeillLA and HardieDG. Metabolism of inflammation limited by AMPK and pseudo-starvation. Nature, 493: 346–355, 2013.
53.
PaulBY, HongCC, SachidanandanC, BabittJL, DengDY, HoyngSA, LinHY, BlochKD, and PetersonRT. Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. Nat Chem Biol, 4: 33–41, 2008.
54.
PietrangeloA, DierssenU, ValliL, GarutiC, RumpA, CorradiniE, ErnstM, KleinC, and TrautweinC. STAT3 is required for IL-6-gp130–dependent activation of hepcidin in vivo. Gastroenterology, 132: 294–300, 2007.
55.
PradhanAD, MansonJE, RifaiN, BuringJE, and RidkerPM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA, 286: 327–334, 2001.
56.
PrinceOD, LangdonJM, LaymanAJ, PrinceIC, SabogalM, MakHH, BergerAE, CheadleC, ChrestFJ, and YuQ. Late stage erythroid precursor production is impaired in mice with chronic inflammation. Haematologica, 97: 1648–1656, 2012.
57.
Reagan-ShawS, NihalM, and AhmadN. Dose translation from animal to human studies revisited. FASEB J, 22: 659–661, 2008.
58.
RitzE, LavilleM, BilousRW, O'DonoghueD, ScherhagA, BurgerU, De AlvaroF, and InvestigatorsA. Target level for hemoglobin correction in patients with diabetes and CKD: primary results of the Anemia Correction in Diabetes (ACORD) Study. Am J Kidney Dis, 49: 194–207, 2007.
59.
RussellRC, YuanH-X, and GuanK-L. Autophagy regulation by nutrient signaling. Cell Res, 24: 42–57, 2014.
60.
SakamoriR, TakeharaT, TatsumiT, ShigekawaM, HikitaH, HiramatsuN, KantoT, and HayashiN. STAT3 signaling within hepatocytes is required for anemia of inflammation in vivo. J Gastroenterol, 45: 244–248, 2010.
61.
SamA, BusbridgeM, AminA, WebberL, WhiteD, FranksS, MartinN, SleethM, IsmailN, and DaudN. Hepcidin levels in diabetes mellitus and polycystic ovary syndrome. Diabet Med, 30: 1495–1499, 2013.
62.
ShenY, ShenZ, MiaoL, XinX, LinS, ZhuY, GuoW, and ZhuYZ. miRNA-30 family inhibition protects against cardiac ischemic injury by regulating cystathionine-γ-lyase expression. Antioxid Redox Signal, 22: 224–240, 2015.
63.
SilverbergDS, WexlerD, and IainaA. The importance of anemia and its correction in the management of severe congestive heart failure. Eur J Heart Fail, 4: 681–686, 2002.
64.
SuzukiK, OlahG, ModisK, ColettaC, KulpG, GeröD, SzoleczkyP, ChangT, ZhouZ, and WuL. Hydrogen sulfide replacement therapy protects the vascular endothelium in hyperglycemia by preserving mitochondrial function. Proc Natl Acad Sci U S A, 108: 13829–13834, 2011.
65.
TeehanGS, BahdouchD, RuthazerR, BalakrishnanVS, SnydmanDR, and JaberBL. Iron storage indices: novel predictors of bacteremia in hemodialysis patients initiating intravenous iron therapy. Clin Infect Dis, 38: 1090–1094, 2004.
66.
TesfayL, ClausenKA, KimJW, HegdeP, WangX, MillerLD, DengZ, BlanchetteN, ArvedsonT, and MirantiCK. Hepcidin regulation in prostate and its disruption in prostate cancer. Cancer Res, 75: 2254–2263, 2015.
67.
ThomasMC, MacIsaacRJ, TsalamandrisC, PowerD, and JerumsG. Unrecognized anemia in patients with diabetes: a cross-sectional survey. Diabetes Care, 26: 1164–1169, 2003.
68.
VecchiC, MontosiG, GarutiC, CorradiniE, SabelliM, CanaliS, and PietrangeloA. Gluconeogenic signals regulate iron homeostasis via hepcidin in mice. Gastroenterology, 146: 1060–1069. e3, 2014.
69.
VincentJL, BaronJ-F, ReinhartK, GattinoniL, ThijsL, WebbA, Meier-HellmannA, NolletG, Peres-BotaD, and InvestigatorsA. Anemia and blood transfusion in critically ill patients. JAMA, 288: 1499–1507, 2002.
70.
VlagopoulosPT, TighiouartH, WeinerDE, GriffithJ, PettittD, SalemDN, LeveyAS, and SarnakMJ. Anemia as a risk factor for cardiovascular disease and all-cause mortality in diabetes: the impact of chronic kidney disease. J Am Soc Nephrol, 16: 3403–3410, 2005.
71.
WeissG and GoodnoughLT. Anemia of chronic disease. N Engl J Med, 352: 1011–1023, 2005.
72.
WellenKE and HotamisligilGS. Inflammation, stress, and diabetes. J Clin Invest, 115: 1111–1119, 2005.
73.
WilliamsonDL, BolsterDR, KimballSR, and JeffersonLS. Time course changes in signaling pathways and protein synthesis in C2C12 myotubes following AMPK activation by AICAR. Am J Physiol Endocrinol Metab, 291: E80–E89, 2006.
74.
WinklerJD, JinM, CrewAP, RossiAK, WillardRR, DongH, SiuK, WangJ, GordonDA, and ChenX. Abstract PR08: ARV-330:an androgen receptor PROTAC degrader for prostate cancer. Mol Cancer Ther, 14: PR08, 2015.
75.
WrightingDM and AndrewsNC. Interleukin-6 induces hepcidin expression through STAT3. Blood, 108: 3204–3209, 2006.
YinL-H, ZhengX-Q, LiH-Y, BiL-X, ShiY-F, YeA-F, WuJ-B, and GaoS-M. Epigenetic deregulated miR-375 contributes to the constitutive activation of JAK2/STAT signaling in myeloproliferative neoplasm. Leuk Res, 39: 471–478, 2015.
78.
YoshimuraA and YasukawaH. JAK's SOCS: a mechanism of inhibition. Immunity, 36: 157–159, 2012.
79.
ZangM, XuS, Maitland-ToolanKA, ZuccolloA, HouX, JiangB, WierzbickiM, VerbeurenTJ, and CohenRA. Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor–deficient mice. Diabetes, 55: 2180–2191, 2006.
80.
ZhouG, MyersR, LiY, ChenY, ShenX, Fenyk-MelodyJ, WuM, VentreJ, DoebberT, and FujiiN. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest, 108: 1167–1174, 2001.
81.
ZhouX, CaoY, AoG, HuL, LiuH, WuJ, WangX, JinM, ZhengS, and ZhenX. CaMKKβ-dependent activation of AMP-activated protein kinase is critical to suppressive effects of hydrogen sulfide on neuroinflammation. Antioxid Redox Signal, 21: 1741–1758, 2014.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
